Introduction
In the last decade, the reuse of percutaneous transluminal coronary angioplasty (PTCA) equipment has been repeatedly discussed in the cardiological and infection control literature. Interest in this problem is growing since the frequency of PTCA procedures is increasing and cost containment in health care has been recognized as a necessity even in industrialized countries.
Single-use devices in medicine were first developed in order to diminish the cost of reprocessing multi-use products. New materials have now permitted wider use of single-use products at lower cost compared with the cost for reprocessing and repackaging of multi-use devices. However, the development of expensive and highly sophisticated catheters in cardiology has raised costs to the point where the debate over reuse has once again arisen.
The designation 'single use device' denotes exclusively the manufacturer's definition and not the intended purpose as per legislation. In general, manufacturers are not interested in the reprocessing of their single use devices and hence refuse to give any information as to whether and how their single use devices can be reprocessed and resterilized. A company, for example, can decide to designate a stainless steel forceps for single use only, even though it can be safely resterilized.
Different institutions and countries have adopted contradictory policies toward reuse. While Canada seems to be in the forefront of implementing a reuse policy, hospitals in the United States tend to fear legal consequences [1, 2] . In most countries, the legal situation is often vague. Although the reuse of angioplasty balloon catheters is common practice in many countries, surprisingly few clinical studies on the reuse of PTCA equipment are available.
The intention of this paper is to review the literature on reuse of PTCA equipment, interpret the current state of knowledge and present the main arguments for and against reuse of balloon catheters.
Reuse protocols for PTCA catheters
For a number of reasons it has been difficult to define the best method of resterilizing PTCA catheters, especially balloon catheters: First, there are few data on the durability of PTCA catheter material. Second, PTCA catheters are fragile and thus there is an increased risk of damaging the catheter during reprocessing manipulation. Third, PTCA catheters are long and have narrow lumens and thus it is difficult to visibly evaluate whether the cleaning process has been successful or not. Additionally, PTCA catheters enter a sensitive area of the vascular system where wounding and/or infection can rapidly lead to a fatal outcome. While these conditions also exist for other catheters used in cardiology, particular attention must be paid to the mechanical integrity of the balloon and the whole pressure system. Other PTCA equipment, for example atherectomy devices or guide wires, are either too complicated to reprocess or too inexpensive to make reprocessing economically profitable. Many hospitals are routinely reusing balloon catheters, but only a few seem to follow validated and standardized reuse protocols [3] [4] [5] . Ethylene oxide is the most common method of sterilizing PTCA equipment, since catheter material does not tolerate heat sterilization and the narrow lumen is penetrated best by volatile substances [4, [6] [7] [8] [9] . The major disadvantages of ethylene oxide sterilization are its toxicity, its ozone depleting effect, and the fact that residual fluid in the balloon could reduce the sterilizing effect [10] . For this reason Mak et al. [6] recommended avoiding saline during reprocessing and re-sterilization of the catheters when using ethylene oxide because both substances combine to form ethylene chlorohydin, which is toxic. On the other hand, water and ethylene oxide build ethylene glycol which is also toxic. For this reason sterilized catheters must be aerated sufficiently to allow diffusion of potential toxins [6] . Recently, alternative reuse protocols have been developed. Bryce and co-workers examined a largely automated sterilizing system using peracetic acid [11] . The sterilizing effect was safe and the machine also performed pressure and patency tests on the mechanical property of the balloon catheter. Grimandi and co-workers presented a sterilizing protocol using gamma ray irradiation at 35 Kgray after various cleaning steps including the use of a decontaminant solution in an ultrasound chamber [7] . The authors' conclusion, however, was that this protocol did not reliably sterilize balloon catheters.
The first clinical trial comparing the use of new and reused balloon catheters was published by Plante and colleagues whose reuse protocol was based on ethylene oxide sterilization [9] . Reused catheters had a lower success rate than new ones. However, various authors have suggested that the detected differences may have been caused mainly by a sampling bias, since Plante compared two different centres with an obviously different patient population [6, 12, 13] . In a re-analysis of the study Mak, Plante, and other co-workers demonstrated through stepwise logistic regression analysis that adverse effects were not associated with the reuse of the equipment but rather to other established risk factors of the patient [14] . Most authors agree that only randomized clinical trails would be able to clarify this uncertainty. Only one randomized controlled trial has been performed since Plante's publication: In 1995 Burton and co-workers conducted a prospective randomized controlled trial of 1,033 PTCA procedures [15] . No significant difference in safety and efficacy between new and reused balloon catheters was found. To our knowledge however, those preliminary results have not been published in detail. Browne and colleagues recently published their clinical experience with reused PTCA equipment in 107 patients and found no evidence for an increased rate of complications [1] . Similar experience was reported from Hadassah University Hospital in Israel where PTCA balloon catheters are routinely being reused once [16, 17] .
Sterility
The incidence of infections after PTCA is low. Published figures on incidence rates or infectious complications after PTCA range from 0·07% to 0·6%, depending on the size of the population and whether the survey was conducted retrospectively or prospectively [18] [19] [20] . A difference in risk for infectious complications between new and reused catheters will be difficult to prove. Even if a 50% increase in infection risk could be attributed to use of reprocessed PTCA catheters, a controlled clinical trial would need over 13 600 procedures in new and reprocessed catheters to detect a significant difference. Thus assessing efficacy of reprocessing procedures must be based on experimental studies in which PTCA catheters are challenged with a bacterial load before applying the reuse protocol and then testing for bacterial growth. For this purpose cultures were made from solutions rinsed through the lumen of the catheter or the catheter was cut into pieces and placed in a culture media. Provided that effective cleaning preceded the above mentioned sterilization procedures, bacterial growth could not be detected [4, 7, 11] . In one such study, Bentolila found that ethylene oxide sterilization was no longer effective if contaminated blood had not been washed off the catheter but deliberately dried on the inside and outside of the catheter before sterilization [4] . This finding underscores the importance of careful and standardized cleaning before sterilization of the catheters. In addition, it should be noted that none of the studies has examined the effect of storage on the sterility of the product [11] . Although most studies have focused on bacterial contamination, viral infections, especially human immunodeficiency virus (HIV) or Hepatitis B, are of major concern. However, both viruses are more sensitive to disinfection procedures than most bacteria and are therefore unlikely to cause additional risk [6] . In one study catheters were contaminated with 10 000 times the typical viral burden in circulating blood of patients with AIDS or hepatitis B virus infection. After processing with ethylene oxide, the catheters were found to be sterile [1] . The Conseil d'E uvaluation des Technologies de la Santé (CETS) in Canada, has recently addressed the potential risk of transmission of new variant CreutzfeldJakob-Disease (nvCJD) in the context of reuse of single use catheters. Given the available data, the potential risk of blood-borne transmission of prions cannot be estimated, but appears to be very low. Likewise, it is not clear whether this is a particular problem for reuse of single use devices or whether the uncertainty actually includes sterilization of any device, whether it is built for reuse or not. For the latter, the consequences for hospital hygiene would be tremendous [21] . Collingnon et al. estimated the possible incidence of cross-infection in Australia due to reprocessed single use medical devices in general, not only PTCA catheters [22] . An assumed 2% prevalence of transmissible infections in blood, and an infection transmission risk of 1/500 would lead to 40 cases of cross-infections for every million procedures performed with reused medical devices each year (0·004%) [22] . In some studies, the surface of the PTCA catheters was examined by electron microscopy scans which revealed organic debris deposited on the surfaces. The clinical consequences of such findings are not clear [7, 4, 23] . In two independent studies Grimandi et al. [7] and Yang et al. [23] concluded that if residual organic material is found on the catheter surface (and it may be only through electron microscopy), the reuse protocol has to be discarded. Bentolila argues that organic debris does not necessarily represent a risk if the material is sufficiently adherent to the surface [4] . We also do not know the extent to which organic debris would be found on other surgical and invasive devices commonly accepted for reuse, if their surfaces were examined by electron microscopy.
Pyrogens
Another concern when reusing PTCA catheters is the risk of endotoxic reactions caused by pyrogenic substances. Such complications are characterized by hypotension, fever and chills [24, 25] . In the Grimandi study, pyrogenic substances were found on all batches of reused catheters but no comparison was made with new catheters [7] . Early studies with cardiac catheters (not only PTCA catheters) were not able to demonstrate significant differences in the incidence of endotoxic reaction or fever between new and reused devices [6, 24, 26] . Jacob suggests that good cleaning and rinsing procedures with pyrogen-free water can ensure that reused catheters have no more pyrogens than new catheters [27] .
Mechanical integrity
Due to the fragility of PTCA balloon catheters, the mechanical integrity after reuse has attracted the attention of various researchers. The results of the studies presently available are contradictory. Experiments conducted at the Sacré-Coeur Hospital, Quebec, included the measurement of the maximum tensile load and the elongation of the catheters at rupture. Neither measure changed after a reuse protocol with ethylene oxide [4] . Grimandi found that after irradiation with 35 Kgray the profiles of the inflated balloon did not change and the burst pressure was above the maximal pressures recommended by the manufacturer. Catheters of different brands showed different resistance to breakage. Some catheters showed a 30% drop in resistance. However, the force required to break a catheter always exceeded the force usually exerted upon catheters during clinical use [7] . Bryce and co-workers examined an automated reprocessing method for PTCA balloon catheters based on peracetic acid. Up to 140 reprocessing cycles were performed with 42 catheters. Five catheters had to be discarded because the mechanical integrity was affected. The authors observed that most of the damaged catheters occurred at the beginning of the study when the users did not have sufficient experience in placing the catheter into the machine without it kinking [11] . An observation independent of the different protocols has been the fact that deflated balloons generally do not regain the tight shape of new balloons [6, 7, 9] . This has led to the suspicion that reused balloon catheters may not pass very narrow lumens as easily as new ones [6] . Browne and colleagues, however, did not observe any practical differences during PTCA procedures with reused balloon catheters [1] . Nevertheless, they stress that a rigorous test on the compliance and deflated profile of the balloon must be passed before a balloon catheter is to be allowed for reuse. Mussivand and co-workers have outlined a protocol by which the mechanical integrity of reused catheters can be assessed [28] .
Economic savings
PTCA catheters are reused by hospitals only for reasons of economy. Browne and colleagues estimate that in the United States savings due to reuse of 50% of PTCA catheters may exceed US$50 million per year [1] . However, such estimates have to be interpreted carefully since the savings effect of a reuse strategy may not be as obvious as it appears. Many factors have to be taken into account in order to realistically model the economic effect of catheter reuse. One point is that the savings due to reuse decrease with the number of reuses. In balloon catheters the savings are minimal after the second or third reuse cycle [9, 27] . A cost efficacy model presented by Milandri and Saviotti underscores the effect of the price of one device and the frequency by which PTCA is performed in an institution [29] . In some countries, however, prices of PTCA catheters have decreased in recent years and existing cost effectiveness studies may have to be repeated.
Additional technical investments and hospital staff involved in reuse and cost for the development of reuse protocols, training of staff, and many more aspects have to be taken into account when calculating the cost for a reuse protocol [3, 22] . The efficiency for reuse also depends on the frequency of PTCAs performed [30, 31] . The number of balloon catheters used for a single dilatation procedure has a much
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higher impact on the overall cost than the utilization of new or used catheters. Cost containment may therefore also be accomplished by a change in technique rather than through reuse of PTCA balloon catheters [17] . Another aspect is the cost of the PTCA catheter; within Europe balloon catheters of the same brand were found to have up to a fivefold difference in price. While prices fall in one country, they increase in another [32] . If reuse is implemented on a large scale, the number of catheters sold will decrease significantly and thus cause an increase in price and perhaps keep manufacturers from developing new products [31, 33] . As Rozenman correctly pointed out, it becomes clear that the efficiency of reuse must be calculated individually for the institution that intends to adopt such a strategy, taking into account the factors above [17] . Remodelling for cost-efficacy may be necessary, if factors such as price of PTCA equipment or the model of the catheter change over time [2, 32] .
Legal and ethical issues
It is commonly understood that reuse of PTCA balloon catheters is ethical only if the rate of adverse effects is equal or less than that associated with the use of new catheters [34] . The scientific data available to date does not permit a firm conclusion on this question [5] . Considering the reanalysis of Plante's results, there are good reasons to assume that there is no additional risk associated with PTCA catheter reuse [14] . On the other hand, the judicial view on this issue may be controversial. In Canada, the health department has supported the statement of the Conseil D'évaluation des Technologies de la Santé (CETS) in favour of reusing single-use cardiac catheters in an official statement [21, 35, 36] . In India, a special committee of the Cardiology Society of India has recommended the reuse of PTCA catheters [8] .
In some countries like England and France, the government policy is that reuse of devices is forbidden if they are labelled for single use only [7, 37] . In Germany reprocessing is not considered to constitute manufacture, thus a new CE mark is not required for reprocessed instruments [38] . The European Union produced legislation applicable to all medical devices placed on the EU market in order to harmonize the legislation on its territory: reuse is not forbidden, but the directives state that in reprocessing a single use device, the user becomes subject to the same requirements as the original manufacturer. Thus, a new CE mark would need to be applied to the reprocessed device. All obligations, including tests for biocompatability, sterility, quality control and documentation would fall to the reprocessor [37] . Apparently, in most non EU countries, the legal situation is not completely clear [2, 6, 36] . In a recent survey of 100 patients scheduled for PTCA in Cleveland, Ohio, one third did not want reprocessed catheters to be used on them [2] . Complications of PTCA will always occur, with new as well as with reused equipment. Some authors claim that with a substantial proportion of patients fearing the reuse of the PTCA balloon catheters it is likely that some of the patients who have experienced complications could attempt a lawsuit and eventually win the case [2, 6, 31] . If the cost of such lawsuits were added to the cost-efficacy model, the reuse policy may indeed be more costly for a hospital than the use of new catheters [2] .
Conclusions
The discussion on reuse of PTCA balloon catheters contains a variety of aspects that are difficult to weigh. Nevertheless, two conclusions can be drawn: (1) Even assuming that no additional clinical risk is associated with PTCA catheter reuse, the decision to adopt or reject a reuse policy has to be based on a careful risk assessment and on the individual situation at each hospital. Factors to consider include technical and personnel resources of the institution, frequency of PTCA procedures, economical and legal environment etc. (2) The review of the literature shows that authors tend to come to two contradictory conclusions as far as patient safety is concerned. One group of authors claims the PTCA balloon catheters are already being reused in many countries and that there is no evidence for an increased risk. The other group sees a risk in the presence of organic debris in reused balloon catheters, which raises both health and legal issues.
Both conclusions are plausible. However, to date there is not sufficient scientific evidence to either prove or to disapprove the safety of reprocessed PTCA balloon catheters. It is unlikely that clinical trials will ever come up with a clear answer to the problem.
Given the present situation, the best solution to the controversy may be an international committee that develops and updates standard operating procedures for PTCA catheter reuse. Those procedures should be based on the latest scientific evidence and should take the experience of those countries into account that already routinely use reprocessed PTCA catheters.
